Author(s): Laurence A, Pesu M, Silvennoinen O, OShea J
Abstract Share this page
Janus kinases (Jaks) are critical signaling elements for a large subset of cytokines. As a consequence they play pivotal roles in the patho-physiology of many diseases including neoplastic and autoimmune diseases. Small molecule Jak inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand. This review will summarize our current knowledge on these key enzymes and their associated pharmaceutical inhibitors.
This article was published in Open Rheumatol J
and referenced in Immunotherapy: Open Access